The Challenge and Management of Clinical Trials in Integrative Cancer during the COVID-19 Pandemic Worldwide
Integr Cancer Ther
.
2021 Jan-Dec:20:1534735421991218.
doi: 10.1177/1534735421991218.
Authors
Geliang Yang
1
2
,
Min Li
1
,
Huiqing Zhang
3
,
Yufei Yang
4
Affiliations
1
Department of Medicine, Shanghai Clinical Research Center, Shanghai, China.
2
Department of Traditional Chinese Medicine, the Second Medical Center, Chinese PLA General Hospital, Beijing, China.
3
Department of Traditional Chinese Medicine, Naval Medical University, Shanghai, China.
4
Department of Oncology Diagnosis and Treatment, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China.
PMID:
33543656
PMCID:
PMC7869149
DOI:
10.1177/1534735421991218
No abstract available
Publication types
Letter
MeSH terms
COVID-19 / epidemiology*
Clinical Trials as Topic / methods
Humans
Integrative Oncology / methods
Neoplasms / drug therapy*
Neoplasms / therapy*
Pandemics
SARS-CoV-2 / isolation & purification